Article ; Online: Global research trends and hotspots of Helicobacter pylori eradication based on clinical trial registration platforms: A cross-sectional analysis.
Clinics and research in hepatology and gastroenterology
2023 Volume 47, Issue 10, Page(s) 102233
Abstract: Background: This study aimed to obtain an overview of clinical trials on Helicobacter pylori (H. pylori) eradication and analyze the global trends and hotspots in this field.: Methods: We collected the data from clinical trials focused on H. pylori ... ...
Abstract | Background: This study aimed to obtain an overview of clinical trials on Helicobacter pylori (H. pylori) eradication and analyze the global trends and hotspots in this field. Methods: We collected the data from clinical trials focused on H. pylori eradication in the primary clinical trial registries from 2000 to 2022 in the world. Then we analyzed the research trends and hotspots in H. pylori eradication regimens in different regions at different periods. Results: A total of 780 clinical trials were included, which were mainly conducted in Asia (682), followed by Europe (59), Africa (20), North America (16), South America (7), Oceania (2). The most active countries were China (343), Iran (140), South Korea (63), and Japan (73). "Bismuth-containing quadruple therapy (BQT)" was the most studied regimen (159, 20.38 %). Additionally, clinical trials focused on potassium-competitive acid blockers (P-CABs)-based therapy, probiotics, and high-dose dual therapy (HDDT) were constantly increasing. BQT received the most attention in China (26.53 %) and Iran (22.14 %), while it was tailored therapy in South Korea (23.29 %). P-CABs-based therapy was the main reseach hotspot in Japan (61.90 %). Conclusion: How to eradicate H. pylori infection has been a heated research topic. BQT, P-CABs-based therapy, probiotics, and HDDT attracted the most attention in recent years. |
---|---|
MeSH term(s) | Humans ; Anti-Bacterial Agents/therapeutic use ; Helicobacter pylori ; Cross-Sectional Studies ; Proton Pump Inhibitors/therapeutic use ; Drug Therapy, Combination ; Helicobacter Infections/drug therapy ; Bismuth/therapeutic use ; Amoxicillin/therapeutic use ; Treatment Outcome |
Chemical Substances | Anti-Bacterial Agents ; Proton Pump Inhibitors ; Bismuth (U015TT5I8H) ; Amoxicillin (804826J2HU) |
Language | English |
Publishing date | 2023-10-24 |
Publishing country | France |
Document type | Journal Article |
ZDB-ID | 2594333-9 |
ISSN | 2210-741X ; 2210-7401 |
ISSN (online) | 2210-741X |
ISSN | 2210-7401 |
DOI | 10.1016/j.clinre.2023.102233 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.